RT Journal Article
SR Electronic
T1 Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e001806corr1
DO 10.1136/jitc-2020-001806corr1
VO 9
IS 11
YR 2021
UL http://jitc.bmj.com/content/9/11/e001806corr1.abstract